Capricor Therapeutics (CAPR) Shares Outstanding (Diluted Average) (2016 - 2026)

Capricor Therapeutics' Shares Outstanding (Diluted Average) history runs 10 years deep, the most recent figure standing at $57.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 25.85% year-over-year to $57.4 million; the TTM figure through Mar 2026 stood at $57.4 million (up 25.85% YoY), while the FY2025 annual figure was $46.5 million, up 31.97% from the prior year.
• Shares Outstanding (Diluted Average) was $57.4 million for Q1 2026 at Capricor Therapeutics, up from $46.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $57.4 million in Q1 2026 to a low of $24.3 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $33.7 million across 5 years, with a median of $31.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) rose 3.97% in 2023, then jumped 45.55% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $24.6 million in 2022, then gained by 9.06% to $26.8 million in 2023, then jumped by 31.52% to $35.2 million in 2024, then surged by 31.97% to $46.5 million in 2025, then grew by 23.57% to $57.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $57.4 million (Q1 2026), $46.5 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.